| Title |
New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
|
|---|---|
| Published in |
Biologics: Targets & Therapy, February 2018
|
| DOI | 10.2147/btt.s140114 |
| Pubmed ID | |
| Authors |
Kenneth Lundstrom |
| Abstract |
Oncolytic viruses have demonstrated selective replication and killing of tumor cells. Different types of oncolytic viruses - adenoviruses, alphaviruses, herpes simplex viruses, Newcastle disease viruses, rhabdoviruses, Coxsackie viruses, and vaccinia viruses - have been applied as either naturally occurring or engineered vectors. Numerous studies in animal-tumor models have demonstrated substantial tumor regression and prolonged survival rates. Moreover, clinical trials have confirmed good safety profiles and therapeutic efficacy for oncolytic viruses. Most encouragingly, the first cancer gene-therapy drug - Gendicine, based on oncolytic adenovirus type 5 - was approved in China. Likewise, a second-generation oncolytic herpes simplex virus-based drug for the treatment of melanoma has been registered in the US and Europe as talimogene laherparepvec. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 117 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 17% |
| Student > Bachelor | 18 | 15% |
| Researcher | 16 | 14% |
| Student > Master | 14 | 12% |
| Student > Doctoral Student | 4 | 3% |
| Other | 16 | 14% |
| Unknown | 29 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 25 | 21% |
| Medicine and Dentistry | 16 | 14% |
| Immunology and Microbiology | 13 | 11% |
| Agricultural and Biological Sciences | 11 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 12 | 10% |
| Unknown | 35 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2024.
All research outputs
#4,838,109
of 25,382,440 outputs
Outputs from Biologics: Targets & Therapy
#57
of 284 outputs
Outputs of similar age
#99,702
of 448,849 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 3 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,849 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them